Skip to main content
Clinical Trials/NCT04226001
NCT04226001WithdrawnNot Applicable

Impact of a Carrier (Infection, Colonization) of Highly Bacteria Resistance on the Patient's

Hospices Civils de Lyon0 sitesStarted: November 16, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Primary Endpoint
Impact of the implementation of Complementary Hygiene Precautions following a carrier of emerging highly resistant bacteria on the quality of life of hospitalized patients

Study Overview

Brief Summary

The quality of life of carriers detected infected or colonized by emerging highly resistant bacteria (BHRe) following the implementation of specific hygiene measures during the discovery of the microorganism has been little studied. To date, there have been no studies to determine the quality of life (QoL) in France of patients with hospitalized HBHRD.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age> 18 years old
  • Have a positive BHRe screening during the hospital stay and / or have a positive BHRe clinical sample during the hospital stay
  • Conscious patients
  • All types of stays in the hospital sector
  • All pathologies

Exclusion Criteria

  • Known patients with BHRe before hospitalization
  • PCH immediately upon admission (history of hospitalization abroad, patients contacted during a previous hospitalization)
  • Cognitive problem
  • Patients not proficient in French (requiring an interpreter)
  • Patients under guardianship

Outcomes

Primary Outcomes

Impact of the implementation of Complementary Hygiene Precautions following a carrier of emerging highly resistant bacteria on the quality of life of hospitalized patients

Time Frame: 12 months

Measurement of the decrease in utility corresponding to the deterioration of the QOL of patients since the implementation of the Additional Hygiene Precautions (PCH) following the discovery of their emerging highly resistant bacteria (BHRe).

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials